Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bright Minds Biosciences Inc. - common stock (NQ:DRUG)

86.25 +3.01 (+3.61%)
Streaming Delayed Price Updated: 11:48 AM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bright Minds Biosciences Inc. - common stock

< Previous 1 2 3 4 5 Next >
News headline image
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model. 
Via The Motley Fool
Topics Intellectual Property Regulatory Compliance
News headline image
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗
This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive... 
Via MarketMinute
News headline image
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
From Bright Minds Biosciences
Via GlobeNewswire
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Via Chartmill
News headline image
Why Did DRUG Stock Rocket 51% Today? ↗
The Phase 2 BREAKTHROUGH trial met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile. 
Via Stocktwits
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Why Bright Minds Biosciences Stock Topped the Market on Monday ↗
The company isn't wasting any time drafting seasoned professionals to help it develop medication for a rare genetic disorder. 
Via The Motley Fool
News headline image
Large Patient Population Is Key Driver For Bright Minds' Growth ↗
BTIG initiates coverage on Bright Minds Biosciences with a Buy rating, citing BMB‑101's potential and key Phase 2 data expected by the end of 2025 
Via Benzinga
News headline image
Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside ↗
Chardan initiates Bright Minds with a Buy rating, citing over $1 billion sales potential for epilepsy drug BMB-101 despite limited clinical data. 
Via Benzinga
News headline image
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Biotechs on the Brink: 2 Stocks With Huge Potential
BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out. 
Via MarketBeat
News headline image
This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month ↗
The reason for the stock's rapid ascent is a mystery. 
Via The Motley Fool
News headline image
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank? ↗
A look at the most-searched tickers on Benzinga Pro for the month of October. Donald Trump and biotech stocks joined the top 10. 
Via Benzinga
Topics Government
News headline image
What's Going On With Bright Minds Biosciences Stock? ↗
Bright Minds Biosciences Inc (NASDAQ:DRUG) shares are trading higher again after soaring last week. The company on Monday announced a new collaboration with brain health-focused AI company Firefly... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
MarketBeat Week in Review – 10/14 - 10/18
Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election. 
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Crude Oil Down Over 1%; American Express Shares Fall After Q3 Results ↗
 
Via Benzinga
News headline image
What's Going On With Bright Minds Biosciences Stock Friday? ↗
Bright Minds Biosciences shares are moving higher on Friday. The company announced a $35 million non-brokered private placement. 
Via Benzinga
News headline image
Dow Falls Over 100 Points; Netflix Posts Upbeat Results ↗
 
Via Benzinga
Topics Stocks
News headline image
Firefly Neuroscience And Bright Minds Advance Phase 1 Study With AI-Driven Data Analysis ↗
Firefly Neuroscience partners with Bright Minds Biosciences to analyze positive Phase 1 data of BMB-101 using advanced AI technology, setting the stage for Phase 2 trials. 
Via Benzinga
Topics Artificial Intelligence
Bright Minds Biosciences (NASDAQ: DRUG) Soars 1800% Amid Short Squeeze Alongside PRSO, ILLR and NIVF
Via AB Newswire
News headline image
Dow Jumps 250 Points; U.S. Bancorp Earnings Top Views ↗
 
Via Benzinga
Topics Stocks
News headline image
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
From Bright Minds Biosciences
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.